Applied Dna Scie SEC Filings

APDN NASDAQ

Welcome to our dedicated page for Applied Dna Scie SEC filings (Ticker: APDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking a company that turns PCR enzymes into industrial-scale synthetic DNA, operates a CLIA-certified molecular diagnostics lab, and tags global cotton with forensic codes is no small task. Applied DNA Sciences weaves biotechnology with supply-chain security, so its SEC filings often span advanced R&D, regulatory lab operations, and licensing for its CertainT platform. Sifting through these multilayered disclosures can feel like decoding a genome.

Whether you need the Applied DNA Sciences annual report 10-K simplified, to dissect an Applied DNA Sciences quarterly earnings report 10-Q filing, or to see how recent Applied DNA Sciences 8-K material events explained future cash needs, our page brings every document into focus. Curious about executive pay? The Applied DNA Sciences proxy statement executive compensation section is one click away. Monitoring insider activity? Get Applied DNA Sciences insider trading Form 4 transactions and Applied DNA Sciences Form 4 insider transactions real-time. Investors regularly search “Applied DNA Sciences SEC filings explained simply” or “understanding Applied DNA Sciences SEC documents with AI”; this hub answers those questions while delivering Applied DNA Sciences earnings report filing analysis you can trust.

How Stock Titan’s AI helps you act faster:

AI-powered summaries translate biotech jargon into plain English, highlighting revenue drivers like Linea DNA and mRNA production.
Real-time alerts the moment a Form 4 or 8-K is posted, so you can track Applied DNA Sciences executive stock transactions Form 4 without delay.
Side-by-side comparisons reveal quarter-over-quarter trends across therapeutic DNA, MDx testing, and CertainT tagging segments.
Search inside any filing to pinpoint R&D spending, clinical milestones, or supply-chain agreements in seconds.

Save hours parsing PDFs and focus on what matters: clear, timely insight into a biotech innovator’s next move.

06/30/2025 04:05 PM

Filing

[8-K] Applied DNA Sciences, Inc. Reports Material Event

Rhea-AI Summary

Magnite, Inc. (MGNI) filed a Form 144 indicating a planned sale of 9,289 common shares worth approximately $204,358 at prevailing market prices. The shares were originally acquired on 02/15/2024 as restricted stock directly from the issuer and will be executed through Morgan Stanley Smith Barney LLC on or about 06/30/2025. Total shares outstanding are reported at 141,110,559, so the proposed sale represents less than 0.01 % of the float.

The filing lists David Buonasera as the selling shareholder, who has already disposed of 12,395 shares over the past three months for gross proceeds of $194,776.59. While the dollar amounts are modest relative to Magnite’s market capitalization, consecutive insider sales can raise sentiment concerns for some investors. The form contains no operational or financial performance data and makes no assertions about Magnite’s fundamentals; it solely discloses the insider’s intent to sell under Rule 144.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.63%

FAQ

What is the current stock price of Applied Dna Scie (APDN)?

The current stock price of Applied Dna Scie (APDN) is $4.9357 as of July 2, 2025.

What is the market cap of Applied Dna Scie (APDN)?

The market cap of Applied Dna Scie (APDN) is approximately 2.4M.

What is the core business of Applied DNA Sciences?

Applied DNA Sciences is focused on the enzymatic production and detection of synthetic DNA and RNA. Its offerings span nucleic acid-based therapeutics, molecular diagnostics, and forensic supply chain security solutions.

How does the company ensure supply chain security?

The company utilizes its proprietary CertainT platform, which combines DNA tagging with isotopic and genomic testing to authenticate materials. This multi-proof approach helps verify origin and protect brands against counterfeiting and diversion.

What are the primary business segments of Applied DNA Sciences?

The company operates across three main segments: therapeutic DNA production services, MDx testing services in molecular diagnostics, and DNA tagging/security products for supply chain authentication.

What technologies support their manufacturing processes?

Applied DNA employs advanced PCR-based enzymatic processes. Its proprietary platforms, such as Linea DNA and Linea IVT, facilitate scalable and high-fidelity production of synthetic DNA and mRNA.

How does the Linea IVT platform enhance mRNA production?

The Linea IVT platform combines DNA IVT templates with a proprietary RNA polymerase, significantly reducing double-stranded RNA contamination and streamlining the mRNA manufacturing workflow.

Who are the typical customers of Applied DNA Sciences?

The company's customers include pharmaceutical and biotechnology firms, diagnostic laboratories, governmental agencies, and industrial manufacturers that require secure, high-quality nucleic acid solutions.

How does Applied DNA Sciences maintain quality and product integrity?

Through rigorous process development and the use of state-of-the-art enzymatic production technologies, the company ensures high fidelity and consistency in its synthetic DNA products, while forensic traceability measures further authenticate its outputs.

In what ways does Applied DNA contribute to innovation in biotechnology?

By integrating advanced PCR technology with forensic authentication and scalable production platforms, the company provides innovative solutions that address both clinical and industrial challenges, fostering greater efficiency and security in genetic medicine and supply chain management.